Goodbye, clean and traditional hardwood. Welcome, a court emblazoned with hundreds of “XII” logos resulting in a polarizing ...

Affluent Medical announces several key appointments for Medical and Clinical affairs. Appointment of Dr. Howard C. Herrmann as strategic Chief Medical Officer for structural heart platform.

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...